Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
June 27, 2025
Not intended for U.S. and UK Media
Eylea™ 8 mg with extended 6-month treatment interval approved in the EU
June 20, 2025
Not intended for U.S. and UK Media
CHMP recommends third indication for Bayer’s Nubeqa™ (darolutamide) for patients with advanced prostate cancer
Discover More
